

Rifaximin Has Marginal Impact on Immune Activation in Immune Non-Responders to Antiretroviral Therapy - ACTG A5286

Allan R. Tenorio¹, Cara C. Wilson², Ellen S. Chan³, Ronald J. Bosch³, Bernard J. Macatangay⁴, Suria Yesmin⁵, Sara W. Read⁶, David M. Margolis⁷, Jeffrey M. Jacobson⁸, Alan L. Landay¹ in behalf of the ACTG A5286 Team

¹Rush University Medical Center, Chicago, IL, US; ²University of Colorado Hospital, Aurora, CO, US; ³Harvard School of Public Health, Boston, MA, US; ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA US; ⁵Social & Scientific Systems, Inc, Silver Spring, MD, US; ⁶National Institute of Health, Bethesda, MD, US; ⁷University of North Carolina, Chapel Hill, NC, US; ⁸Drexel University, Philadelphia, PA, US

BACKGROUND


- Immune activation (%CD38⁺HLA-DR⁺ on CD8⁺ T-cells) predicts disease progression in untreated HIV-1 infection & CD4⁺ T-cell rise with ART.
- Immune activation is associated with elevated markers of gut microbial translocation (MT) from HIV-induced gut mucosal CD4⁺ T-cell depletion.
- HIV⁺ persons with CD4⁺ T-cell <350 cells/mm³ despite suppressive ART - immune non-responders - have higher levels of MT, immune activation and inflammation.
- Rifaximin, a non-absorbable antibiotic, decreases plasma LPS levels in cirrhotics.
- We hypothesized that rifaximin would decrease gut MT, immune activation & inflammation in immune non-responders.

METHODS

- A5286 was a randomized open-label 2-arm pilot study.
- 73 HIV⁺ adults on ART for ≥ 96 weeks with CD4⁺ T-cell < 350 & viral load below assay limit for ≥ 48 weeks were randomized 2:1 to rifaximin 550 mg BID versus no study treatment for 4 weeks.
- %CD38/HLA-DR⁺ and %Ki67⁺ on CD8⁺/CD4⁺ T-cells, LPS, sCD14, IL-6, D-dimer, CRP, sCD163 and sTNFR-II were measured at baseline & weeks 2, 4, 8 and 12.
- Cryopreserved blood samples from 20 age-matched HIV-neg men from the Multicenter AIDS Cohort Study were assayed for biomarker levels to serve as controls.
- Wilcoxon rank-sum tests compared changes between arms.
- Spearman correlations assessed correspondence between biomarker levels, & between biomarker responses to treatment.
- P-values are 2-sided at 5% nominal level without adjustments for multiple testing

RESULTS

Subject Disposition



SAFETY

- No deaths reported.
- 36 (49%) subjects had a primary adverse event: 27 in rifaximin arm and 9 in the no-study-treatment arm.
- No significant difference in maximum primary event grade between the 2 arms.
- None of the grade 3 or 4 events were related to study treatment.
- Adverse events that were possibly/definitely related to study treatment: nausea, constipation, flatulence, anorexia, stomach ache, "feeling sick" and elevated lipase.

Table 1: Baseline demographic, immunologic & virologic characteristics of 65 subjects included in the as-treated analyses.

Characteristic		Rifaximin (N=43)	No Treatment (N=22)
Age (years)	Median (Q1, Q3)	48 (43, 56)	51 (45, 55)
	≥ 60	4 (9%)	3 (14%)
Race/Ethnicity	White Non-Hispanic	19 (44%)	12 (55%)
	Black Non-Hispanic	17 (40%)	3 (14%)
	Hispanic	7 (16%)	6 (27%)
Sex	M	39 (91%)	20 (91%)
Baseline CD4 (cells/mm ³)	Median (Q1, Q3)	251 (179, 286)	223 (167, 280)
Nadir CD4 (cells/mm ³)	Median (Q1, Q3)	50 (22, 71)	40 (10, 88)
Entry HIV-1 RNA	#Undetectable	43 (100%)	22 (100%)
Years since 1 st undetectable HIV-1 RNA	Median (Q1, Q3)	3.3 (2.2, 7.3)	3.9 (2.8, 8.8)

Table 2: Baseline immune biomarker levels in subjects compared to levels in HIV-negative age-matched controls.

Biomarkers	Normal Control (N=20)	Pooled Study Arms at Baseline (N=65)	P-Value
	Median (Q1, Q3)	Median (Q1, Q3)	
Advanced Flow Markers			
% HLA-DR ⁺ CD38 ⁺ of CD8 ⁺	4.05 (2.68, 6.04)	8.14 (5.18, 13.70)	<.001
%HLA-DR ⁺ CD38 ⁺ of CD4 ⁺	1.76 (1.46, 2.42)	4.95 (3.64, 6.06)	<.001
%Ki67 ⁺ of CD8 ⁺	0.50 (0.31, 0.74)	0.71 (0.52, 0.99)	0.014
%Ki67 ⁺ of CD4 ⁺	0.58 (0.46, 1.11)	1.65 (1.39, 2.50)	<.001
Gut Microbial Translocation Markers			
LPS (pg/mL)	84.0 (70.7, 91.3)	103.7 (73.7, 121.2)	0.036
sCD14 (ng/mL)	1,270.9 (1,100.2, 1,464.0)	1,808.9 (1,604.8, 2,161.6)	<.001
Soluble Markers			
IL-6 (pg/mL)	0.9 (0.6, 1.4)	1.2 (0.9, 2.2)	0.016
CRP (ng/mL)	1,126.9 (346.7, 3,175.6)	1,446.9 (730.9, 2,989.2)	0.35
D-dimer (ng/mL)	192.2 (157.1, 239.9)	129.6 (96.0, 213.8)	0.018
sTNFR-II (pg/mL)	2,995.8 (2,319.0, 3,776.8)	4,214.0 (3,186.0, 6,354.4)	<.001
sCD163 (ng/mL)	658.4 (610.3, 771.5)	611.4 (438.1, 743.9)	0.278

RESULTS




Figure 1: Changes in %CD38+HLA-DR+ of CD8+ T-cells from baseline




Figure 2: %CD38+HLA-DR+ of CD8+ T-cells per subject over time in each arm

Table 3: Median log₁₀ change in soluble biomarkers.

Biomarker	Time Period	Treatment Arm	N	Median (Q1, Q3)	95% CI for Median	p-value
Gut Microbial translocation biomarkers						
LPS (log ₁₀ pg/mL)	1. BL – Week 2	Rifaximin	43	-0.01 (-0.09, 0.02)	(-0.05, 0.01)	0.013
		No Study Treatment	22	0.03 (-0.03, 0.11)	(-0.01, 0.15)	
	2. BL – Week 4	Rifaximin	43	0.00 (-0.08, 0.05)	(-0.04, 0.02)	0.44
		No Study Treatment	22	-0.01 (-0.04, 0.05)	(-0.02, 0.05)	
	3. BL – Week 8	Rifaximin	42	-0.01 (-0.12, 0.06)	(-0.06, 0.03)	0.22
		No Study Treatment	21	0.02 (-0.02, 0.08)	(-0.03, 0.08)	
sCD14 (log ₁₀ ng/mL)	1. BL – Week 2	Rifaximin	43	-0.00 (-0.06, 0.04)	(-0.04, 0.02)	0.033
		No Study Treatment	22	0.05 (-0.02, 0.13)	(-0.00, 0.09)	
	2. BL – Week 4	Rifaximin	43	-0.03 (-0.07, 0.06)	(-0.05, 0.01)	0.97
		No Study Treatment	22	-0.03 (-0.05, 0.01)	(-0.07, 0.02)	
	3. BL – Week 8	Rifaximin	42	-0.04 (-0.09, 0.03)	(-0.08, -0.01)	0.049
		No Study Treatment	21	0.01 (-0.05, 0.08)	(-0.03, 0.07)	
Soluble Inflammation Biomarkers						
IL-6 (log ₁₀ pg/mL)	1. BL – Week 2	Rifaximin	43	0.02 (-0.11, 0.15)	(-0.07, 0.07)	0.94
		No Study Treatment	22	-0.05 (-0.11, 0.20)	(-0.10, 0.20)	
	2. BL – Week 4	Rifaximin	43	-0.03 (-0.14, 0.08)	(-0.08, 0.03)	0.33
		No Study Treatment	22	0.05 (-0.13, 0.12)	(-0.06, 0.13)	
	3. BL – Week 8	Rifaximin	42	-0.05 (-0.18, 0.07)	(-0.12, 0.01)	0.025
		No Study Treatment	21	0.05 (-0.08, 0.18)	(-0.02, 0.19)	
CRP (log ₁₀ ng/mL)	1. BL – Week 2	Rifaximin	43	0.00 (-0.26, 0.21)	(-0.14, 0.08)	0.14
		No Study Treatment	22	0.04 (-0.09, 0.32)	(-0.04, 0.27)	
	2. BL – Week 4	Rifaximin	43	-0.08 (-0.29, 0.15)	(-0.20, 0.03)	0.72
		No Study Treatment	22	-0.09 (-0.21, 0.16)	(-0.22, 0.12)	
	3. BL – Week 8	Rifaximin	42	-0.04 (-0.26, 0.13)	(-0.18, 0.03)	0.046
		No Study Treatment	21	0.09 (-0.02, 0.28)	(-0.06, 0.31)	
sTNFR-II (log ₁₀ pg/mL)	1. BL – Week 2	Rifaximin	42	-0.03 (-0.11, 0.03)	(-0.08, 0.01)	0.043
		No Study Treatment	22	0.04 (-0.06, 0.17)	(-0.03, 0.13)	
	2. BL – Week 4	Rifaximin	42	-0.04 (-0.17, 0.09)	(-0.09, 0.02)	0.08
		No Study Treatment	22	0.07 (-0.05, 0.13)	(-0.06, 0.11)	
	3. BL – Week 8	Rifaximin	42	0.04 (-0.07, 0.12)	(-0.02, 0.08)	0.35
		No Study Treatment	21	-0.01 (-0.15, 0.10)	(-0.11, 0.06)	

OTHER RESULTS

- Significant difference was seen in the change in %Ki67⁺CD8⁺ T-cell from baseline to week 4 (p=0.013): median (Q1, Q3) change for the rifaximin arm: -0.12% (-0.27%, 0.12%) vs no-study-treatment arm: 0.12% (-0.07%, 0.27%).
 - No significant differences in the change from baseline to weeks 2/8.
- No significant differences were seen between the arms in change in CD4 T-cell count, CD4 T-cell activation and turn-over, D-dimer, and sCD163.

Table 4: Spearman correlations between baseline biomarker levels & between changes from baseline to week 4 in biomarkers.

Biomarker	LPS			sCD14		
	N	r	P-value	N	r	P-value
Correlation between biomarkers at baseline						
%HLA-DR ⁺ CD38 ⁺ of CD8 ⁺	65	-0.03	0.796	65	-0.10	0.41
IL-6	65	0.21	0.097	65	0.32	0.009
LPS	.	.	.	65	0.19	0.13
CRP	65	0.16	0.193	65	0.26	0.036
sCD14	65	0.19	0.129	.	.	.
D-dimer	65	0.34	0.006	65	0.32	0.009
sTNFRII	65	0.02	0.864	65	0.10	0.44
Correlation between changes in biomarkers from baseline to week 4						
%HLA-DR ⁺ CD38 ⁺ of CD8 ⁺	43	0.12	0.460	43	-0.01	0.95
IL-6	43	-0.20	0.202	43	0.32	0.038
LPS	.	.	.	43	-0.01	0.96
CRP	43	-0.29	0.057	43	0.30	0.054
sCD14	43	-0.01	0.956	.	.	.
D-dimer	43	-0.05	0.758	43	0.23	0.14
sTNFRII	42	0.02	0.897	42	-0.11	0.47

CONCLUSIONS

- While rifaximin for 4 weeks was well-tolerated, it only led to a transient decline in gut MT & had a marginal impact on immune activation in immune non-responders to virally suppressive ART.
- Rifaximin was associated with a significant but minimal post-treatment decrease in systemic inflammation (IL-6 & CRP). Whether longer use of rifaximin will impact systemic inflammation is unknown, and may be worth exploring.
- The absence of correlations between baseline T-cell activation, inflammation & MT levels, & between rifaximin-mediated changes in T-cell activation & MT suggest that while MT & T-cell activation are high in immune non-responders, these processes may only be weakly or indirectly linked mechanistically.
- Changes in sCD14 were more closely linked to changes in systemic inflammatory markers (IL-6) that are associated w/ morbidity in HIV⁺ persons on ART.

A5286 Team

Co-Chairs
 • Allan Tenorio, M.D.
 • Cara Wilson, M.D.
Statisticians
 • Ellen Chan, M.Sc.
 • Ronald Bosch, Ph.D.
DAIDS Clinical Representative
 • Sarah W. Read, M.D.
Clinical Trials Specialist
 • Suria Yesmin, B.S.
Immunologists
 • Bernard J.C. Macatangay, M.D.
 • Alan Landay, Ph.D.
Virologist
 • David M. Margolis, M.D.
 • Jeffrey M. Jacobson, M.D.
 • Ali Keshavarzian, M.D.

Investigators
 • Benigno Rodriguez, M.D.
 • Babafemi Taiwo, M.D.
 • Mariam Aziz, M.D.
 • Rachel Presti, M.D.
 • Steven Deeks, M.D.
 • DAIDS Pharmacist
 • Ruth Eblashah, Pharm.D., M.S., R.Ph.
 • Data Manager
 • Laurie Myers, M.S., M.T.
Laboratory Technologists
 • Ludan Burrowski, M.Sc.
 • Jill Plants, B.S.
CSS Representative
 • David A. Palm, M.S.
Laboratory Data Managers
 • Derek Weibel, M.S.Ed.
 • Field Representative
 • Beverly Putnam, R.N., A.N.P.

Acknowledgements

Patients
 • ACTG and DAIDS Leadership
Study staff:
 CORNELL CRS
 U. OF ALABAMA AT BIRMINGHAM
 UCLA MEDICAL CENTER
 U. OF MARYLAND, INST OF HUMAN VIROLOGY
 HIV PREVENTION & TREATMENT CRS/COLUMBIA
 GEORGETOWN UNIVERSITY
 NY UNIV. HIV/AIDS CRS
 THE FORCE DE LEON CTR. CRS
 ROCHESTER
 RUSH PRESBYTERIAN/ST. LUKE'S
 U. OF CINCINNATI COL. OF MED.
 AIDS CARE CRS/ROCHESTER
 CASE WESTERN RESERVE
 DUKE UNIV. MED. CTR. ADULT CRS
 THE MIRIAM HOSPITAL RHODE ISLAND
 NORTHWESTERN
 PITTSBURGH
 STANFORD UNIVERSITY
 UNIVERSITY OF MIAMI
 UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA
 WASHINGTON UNIVERSITY
 HARVARD, MASSACHUSETTS GENERAL
 METROHEALTH MEDICAL CENTER, CLEVELAND
 BETH ISRAEL DEACONESS
 BRIGHAM AND WOMEN'S HOSPITAL
 HARVARD, MASSACHUSETTS GENERAL
 UNIVERSITY OF COLORADO HEALTH SCIENCES CENTER
 UNIVERSITY OF NORTH CAROLINA
 UNIVERSITY OF PUERTO RICO
 UNIVERSITY OF WASHINGTON